Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Hybrigenics SA's Hybrigenics Services Acquires Yeast Two-hybrid Activities of Dualsystems Biotech's
Hybrigenics SA announced that its subsidiary Hybrigenics Services acquired the yeast two-hybrid (Y2H) activities of Dualsystems Biotech, a privately owned Swiss company based in Schlieren near Zurich. Financial terms are not disclosed. This operation is to improve Hybrigenics Services' commercial reach in German-speaking territories, Eastern Europe and China. Hybrigenics Services will also get exclusive ownership of a patented Y2H screening technology specifically suited to membrane proteins.
Latest Developments for Hybrigenics SA
- Hybrigenics SA Announces Positive Partial Results of Clinical Study of Inecalcitol in Chronic Lymphocytic Leukemia
- Hybrigenics SA Announces Initial Results from Clinical Phase 2 Trial of Oral Inecalcitol in Moderate to Severe Psoriasis
- Hybrigenics SA Starts Phase II Clinical Trial of Inecalcitol in Psoriasis
- Hybrigenics SA Announces Its Specific Inhibitor of Ubiquitin-Specific Protease 7 (USP7) is Cytotoxic for Chronic Lymphocytic Leukaemia (CLL) Cells in Vitro
Latest Key Developments in Biotechnology
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Novation Holdings Inc Announces Acquisition Of Controlling Interest In Solar Energy Initiatives Inc
- La Jolla Pharmaceutical Co Announces FDA Acceptance Of IND For LJPC-501
- Portola Pharmaceuticals Inc Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity Of Eliquis
- Share this
- Link this
- Digg this
Follow Reuters